Preclinical Safety Evaluation of AAV2-sFLT01— A Gene Therapy for Age-related Macular Degeneration

AAV2-sFLT01 is a vector that expresses a modified soluble Flt1 receptor designed to neutralize the proangiogenic activities of vascular endothelial growth factor (VEGF) for treatment of age-related macular degeneration (AMD) via an intravitreal injection. Owing to minimal data available for the intr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: MacLachlan, Timothy K, Lukason, Michael, Collins, Margaret, Munger, Robert, Isenberger, Elisabete, Rogers, Cindy, Malatos, Shana, DuFresne, Elizabeth, Morris, James, Calcedo, Roberto, Veres, Gabor, Scaria, Abraham, Andrews, Laura, Wadsworth, Samuel
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group 2011
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3034852/
https://ncbi.nlm.nih.gov/pubmed/21119620
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2010.258
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge